BioDelivery Sciences International, Inc. (BDSI) Stock Analysis

BioDelivery Sciences International, Inc. (BDSI) Healthcare & Pipeline Overview

BioDelivery Sciences International, Inc. (BDSI) develops and commercializes specialty pharmaceuticals for chronic conditions, leveraging its patented BioErodible MucoAdhesive drug-delivery technology. With a focus on pain management and opioid-induced constipation, BDSI offers innovative treatments like BELBUCA and Symproic, operating as a subsidiary of Collegium Pharmaceutical, Inc.

What Is the Investment Thesis for BDSI?

BioDelivery Sciences International, Inc. (BDSI), now a subsidiary of Collegium Pharmaceutical, presents a focused investment profile centered on its established portfolio of pain management and gastrointestinal therapeutics. Key to its value is BELBUCA, a buprenorphine buccal film for chronic pain, and Symproic, for opioid-induced constipation. Growth catalysts include expanding market penetration for ELYXYB and ONSOLIS. Potential risks involve competition from generic alternatives and the integration challenges post-acquisition by Collegium Pharmaceutical.

Based on FMP financials and quantitative analysis

BDSI Key Highlights

Market Cap of $577M reflects BDSI's valuation within the specialty pharmaceutical sector.

• P/E Ratio of 6.82 indicates a potentially undervalued stock relative to its earnings.
• Profit Margin of 50.9% showcases strong profitability and efficient cost management.
• Gross Margin of 86.0% highlights the high value and pricing power of BDSI's pharmaceutical products.
• BDSI operates as a subsidiary of Collegium Pharmaceutical, Inc. since March 18, 2022, influencing its strategic direction.

Who Are BDSI's Competitors?

BDSI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BDSI's Key Strengths?

Proprietary drug delivery technology (BEMA).

• Established portfolio of branded products.
• High gross and profit margins.
• Focus on specialized therapeutic areas.

What Are BDSI's Weaknesses?

Reliance on a limited number of key products.

• Exposure to generic competition.
• Dependence on Collegium Pharmaceutical, Inc. post-acquisition.
• Potential regulatory challenges.

What Could Drive BDSI Stock Higher?

Continued expansion of BELBUCA market share in chronic pain management.

• Increased adoption of Symproic for opioid-induced constipation.
• Potential new product launches or line extensions within the next 1-2 years.
• Strategic partnerships or acquisitions to expand the product portfolio.

What Are the Key Risks for BDSI?

Insider selling — insiders were net sellers of roughly $2.9M recently.

• Generic competition eroding market share of key products.
• Regulatory changes impacting pricing and market access.
• Product liability claims related to pharmaceutical products.
• Dependence on Collegium Pharmaceutical, Inc. for strategic direction and resource allocation.

What Are the Growth Opportunities for BDSI?

• Expansion of BELBUCA Market Share: BELBUCA, a buprenorphine buccal film for chronic pain, represents a significant growth opportunity. The chronic pain market is estimated to reach $105.9 billion by 2028, growing at a CAGR of 3.6%. BDSI can increase its market share by targeting patients who require long-term opioid treatment and for whom alternative options are inadequate. This involves strategic marketing, physician education, and patient support programs. The timeline for significant market penetration is within the next 3-5 years, contingent on successful commercialization efforts.
• Increased Adoption of Symproic for OIC: Symproic, used for opioid-induced constipation (OIC), offers a growth avenue given the rising prevalence of opioid prescriptions. The OIC market is projected to reach $2.1 billion by 2027. BDSI can capitalize on this by focusing on patients with chronic non-cancer pain, including those with pain related to prior cancer treatment. Effective marketing and awareness campaigns targeting both physicians and patients are crucial. The timeline for increased adoption is within the next 2-4 years, dependent on successful market penetration strategies.
• BDSI can leverage its existing sales infrastructure to promote ELYXYB to neurologists and primary care physicians. Emphasizing the benefits of a liquid formulation for rapid absorption can differentiate ELYXYB from other migraine treatments. The timeline for significant market impact is within the next 1-3 years, contingent on successful commercial launch and market acceptance.
• Strategic Partnerships and Acquisitions: BDSI can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring complementary products can enhance its competitive position. This includes exploring opportunities in related therapeutic areas or geographic markets. The timeline for realizing benefits from partnerships or acquisitions is variable, ranging from immediate to long-term, depending on the nature of the deal and integration process.
• Advancements in Drug Delivery Technology: BDSI's patented BioErodible MucoAdhesive (BEMA) technology and other drug delivery systems offer a competitive advantage. Continued investment in research and development to enhance these technologies can lead to new product formulations and improved patient outcomes. This includes exploring applications in other therapeutic areas and developing novel delivery methods. The timeline for realizing benefits from technological advancements is ongoing, with continuous innovation driving long-term growth.

What Are BDSI's Competitive Advantages?

• Patented BioErodible MucoAdhesive (BEMA) drug-delivery technology provides a competitive edge.
• Established portfolio of branded pharmaceutical products with strong market presence.
• Specialized focus on pain management and gastrointestinal therapeutics.
• Regulatory exclusivity for key products, protecting market share.

What Does BDSI Do?

BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products for the treatment of chronic conditions. Founded in 1997 and headquartered in Raleigh, North Carolina, BDSI has focused on utilizing its patented BioErodible MucoAdhesive (BEMA) drug-delivery technology and other advanced delivery systems to improve patient outcomes. The BEMA technology allows for the administration of drugs via a small, erodible polymer film applied to the buccal mucosa, offering enhanced absorption and bioavailability. BDSI's portfolio includes BELBUCA, a buprenorphine buccal film indicated for the management of chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Another key product is Symproic, a peripherally acting mu-opioid receptor antagonist (PAMORA) used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including those with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. Additionally, BDSI offers ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults, and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc., marking a new chapter in its evolution and strategic direction within the pharmaceutical landscape.

What Products and Services Does BDSI Offer?

• Develop and commercialize pharmaceutical products for chronic conditions.
• Utilize patented BioErodible MucoAdhesive (BEMA) drug-delivery technology.
• Offer BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.
• Provide Symproic, a PAMORA for opioid-induced constipation.
• Market ELYXYB, a celecoxib oral solution for migraine.
• Supply ONSOLIS, a fentanyl buccal soluble film for breakthrough pain in cancer patients.

How Does BDSI Make Money?

• Develop and patent novel drug delivery technologies.
• Commercialize branded pharmaceutical products through direct sales and marketing.
• Generate revenue through product sales to wholesalers, pharmacies, and healthcare providers.
• Focus on specialty markets with high unmet medical needs.

What Industry Does BDSI Operate In?

BioDelivery Sciences International, Inc. operates within the specialty pharmaceutical industry, which is characterized by the development and marketing of branded drugs that address specific medical needs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug delivery systems. Competition is intense, with companies vying for market share through innovation and strategic partnerships. BDSI's focus on pain management and opioid-induced constipation positions it within a high-demand segment, but it faces competition from both established pharmaceutical giants and smaller, innovative biotech firms. The industry is subject to stringent regulatory oversight and pricing pressures, impacting profitability and market access.

Who Are BDSI's Key Customers?

• Patients suffering from chronic pain requiring long-term opioid treatment.
• Adult patients with opioid-induced constipation due to chronic non-cancer pain.
• Adults experiencing migraine with or without aura.
• Cancer patients requiring management of breakthrough pain.

Company Profile

BioDelivery Sciences International, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Raleigh, US. The company is led by CEO Herm Cukier. BDSI has traded publicly since 2002.

BioDelivery Sciences International, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.76 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for BioDelivery Sciences International, Inc. stands at 57.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 26.1%, showing how much profit it generates from its asset base. BDSI trades at a trailing price-to-earnings ratio of 6.82, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 14.7%, the inverse of the P/E and a quick read on earnings relative to price.

BDSI Valuation & Market Position

With a $577M market cap, BioDelivery Sciences International, Inc. sits in the small-cap segment of the market.

BioDelivery Sciences International, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 350.2% above estimates on average.

The most recent 12 insider filings for BioDelivery Sciences International, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.2M shares disposed (about $2.9M), a signal worth weighing alongside the fundamentals.

BDSI Financials

BDSI Latest News

BDSI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources